论文部分内容阅读
目的探讨急性进展性脑梗死的有效治疗措施,从而改善急性进展性脑梗死的预后。方法将135例急性进展性脑梗死患者随机分为3组:治疗组45例,采用依达拉奉30mg+NS100ml静滴,30min滴完,每日2次,连用14天,同时低分子肝素钙0.4ml腹部皮下注射,每日2次,连用7天,余治疗同对照组;抗凝组45例,低分子肝素钙0.4ml腹部皮下注射,每日2次,连用7天,余治疗同对照组;对照组45例,血栓通300mg+NS250ml静点,每日一次,共14天,胞二磷胆碱0.5+NS100ml静点,每日二次,共14天。结果治疗组疗效明显优于抗凝组和对照组P<0.01,而且抗凝组疗效也高于对照组P<0.05。结论应用依达拉奉与低分子肝素联合治疗急性进展性脑梗死,能有效的控制病情的发展、恶化,疗效显著,使用简便、安全,值得在临床推广应用。
Objective To investigate the effective treatment of acute progressive cerebral infarction and to improve the prognosis of acute progressive cerebral infarction. Methods A total of 135 patients with acute progressive cerebral infarction were randomly divided into 3 groups: treatment group (n = 45), edaravone 30mg + NS100ml intravenous drip 30min drip, twice daily for 14 days, while low molecular weight heparin 0.4ml abdominal subcutaneous injection twice daily for 7 days, the remaining treatment with the control group; anticoagulant group 45 cases, low molecular weight heparin 0.4ml abdominal subcutaneous injection, twice daily for 7 days, the remaining treatment with the control Group; control group of 45 cases, thrombus through 300mg + NS250ml static point, once daily for 14 days, citicoline 0.5 + NS100ml static point twice daily for a total of 14 days. Results The treatment group was significantly better than the anticoagulant group and the control group P <0.01, and the anticoagulant group was also higher than the control group P <0.05. Conclusion The combination of edaravone and low molecular weight heparin in the treatment of acute progressive cerebral infarction can effectively control the progression of the disease, worsen the curative effect, and is simple and safe to use. It is worthy of clinical application.